Search
Isocarboxazid
go.drugbank.com/drugs/DB01247Approved[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. … Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesChymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawnChymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. … [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.
Products: Chymodiactin Injection - 4 Nkat Units/2mlQuizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalcytarabine consolidation, followed by a maintenance monotherapy resulted in a 22% reduction in the risk of death. … [L47426] FLT3-ITD mutation is present in 75% of FLT3-mutated AML, leading to constitutively active FLT3 and thus poorer overall survival and higher risk of relapse.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)ureaCYT-6091
go.drugbank.com/drugs/DB05991ExperimentalIt was under investagtion in clinical trials NCT00356980 and NCT00436410 for the treatment of various cancers. … CYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold
Categories: Compounds used in a research, industrial, or household settingNifurtimox
go.drugbank.com/drugs/DB11820ApprovedInvestigationalOn August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials. … If Chagas disease is left untreated, life-threatening sequelae may result.[L15366] Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease.
Categories: Heterocyclic Compounds, 1-RingIcalcaprant
go.drugbank.com/drugs/DB21651InvestigationalIcalcaprant is under investigation in clinical trial NCT06696755 (A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder … Icalcaprant has a monoisotopic molecular weight of 406.2 Da.
Synonyms: 4-(4-{[(2S)-2-(3-methoxy-1-methyl-1H-pyrazol-4-yl)pyrrolidin-1-yl]methyl}phenoxy)benzamideInterferon Gamma
go.drugbank.com/drugs/DB15753InvestigationalInterferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. … The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Synonyms: IFN-G, IFN-γPimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalIn fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigational[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib. … [L10241] In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: CALQUENCE® 100MGOlaratumab
go.drugbank.com/drugs/DB06043ApprovedInvestigationalStudies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. … It is composed of two heavy chain molecule fragments and 2 light chain fragments.